Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2018 12:00 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma

– Two CRs, four PRs (46% ORR) observed in advanced AITL patients in Phase 2 trial of tipifarnib in PTCL – – AITL and other PTCL patients with high CXCL12 expression experienced 50% ORR and 90%...
November 28, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

– AITL patent expands protection for tipifarnib, provides exclusivity in U.S. to 2037 – – Prospective data from AITL and CXCL12+ cohorts in Phase 2 trial of tipifarnib in PTCL upcoming at ASH 2018 – ...
November 08, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors

Ms. Szela brings expertise in global brand development to Kura as company enters first registration-directed trial SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a...
November 06, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
November 05, 2018 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology Reports Third Quarter 2018 Financial Results and Provides Corporate Update

– Registration-directed trial of tipifarnib in HRAS mutant HNSCC now underway – – Encouraging preliminary clinical activity observed in HRAS mutant SCC cohort – – Preliminary data from AITL and...
November 05, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas

– AIM-HN designed to enroll at least 59 patients with HRAS mutant HNSCC – – Full enrollment expected in two years with response rate as primary endpoint – SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE)...
November 01, 2018 09:00 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Upcoming Presentations at ASH Annual Meeting

SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
October 29, 2018 07:30 ET | Source: Kura Oncology, Inc.

Kura Oncology to Report Third Quarter 2018 Financial Results

SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
October 22, 2018 08:45 ET | Source: Kura Oncology, Inc.

Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC

– Nine patients with HRAS mutant HNSCC experienced tumor size reductions, including six confirmed PRs and two patients with disease stabilization greater than six months – – One additional HNSCC...
September 26, 2018 16:05 ET | Source: Kura Oncology, Inc.

Kura Oncology to Present at Leerink Partners Rare Disease & Oncology Roundtable

SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...